On January 29, 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association issued a joint statement announcing that effective April 1, 2018, 20 commonly prescribed generic drugs will be further reduced to 10% of the cost of the reference brand product. The list of drugs reimbursed at 18% has also grown and now includes almost 50 products. The complete list of products can be found here.
Most generic drugs are reimbursed by public drug plans at 25% of the cost of the reference brand product. Over the past several years, the pCPA and public payors have implemented measures to further reduce the price of certain commonly prescribed products. Initially, reimbursement for a small group of drugs was capped at 18% of the brand price and over time this list has grown.